Top Buy Stocks
Sign In
Invest in AKBA
$3.68
+0.120 (+3.37%)
At Close: Jun 20, 2025
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
08:00am, Wednesday, 04'th Jun 2025
Akebia continues to publish important, clinically relevant data to further physicians' understanding of Vafseo® (vadadustat) Akebia continues to publish important, clinically relevant data to further
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 02'nd Jun 2025
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, g
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
08:00am, Wednesday, 28'th May 2025
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025
08:00am, Tuesday, 27'th May 2025
Vadadustat clinical data on display for nephrologists and healthcare providers Vadadustat clinical data on display for nephrologists and healthcare providers
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
08:00am, Tuesday, 13'th May 2025
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript
12:44pm, Thursday, 08'th May 2025
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor Relations John Butler - Chief Exec
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
09:21am, Thursday, 08'th May 2025
Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Thursday, 08'th May 2025
Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Thursday, 01'st May 2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Thursday, 01'st May 2025
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights
08:00am, Thursday, 01'st May 2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thur
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock
10:00am, Thursday, 10'th Apr 2025
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 02'nd Apr 2025
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
08:00am, Tuesday, 25'th Mar 2025
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
